Gilead's Virus Drug Remdesivir Gains Approval From FDA

The video discusses the FDA approval of Remdesivir, allowing Gilead to market and manufacture the drug more broadly. It also covers the limited effectiveness of convalescent plasma in treating COVID-19, highlighting the challenges in determining the efficacy of therapeutics without extensive trials. The complexity of these trials is due to uncertainties about the presence and role of antibodies in convalescent plasma.

What uncertainties exist regarding the trials for convalescent plasma?

What is the significance of the statement that we still don't have evidence whether or not certain approaches work against novel viruses?